Cynata Therapeutics Ltd (51S)

0.2720
-0.0080(-2.86%)
  • Volume:
    0
  • Bid/Ask:
    0.0000/0.0000
  • Day's Range:
    0.2720 - 0.2720
  • Type:Equity
  • Market:Germany
  • ISIN:AU000000CYP7
  • WKN:A1W8VE

51S Overview

Prev. Close
0.28
Day's Range
0.272-0.272
Revenue
-
Open
0.272
52 wk Range
0.238-0.62
EPS
-
Volume
0
Market Cap
50.17M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,400
P/E Ratio
-
Beta
-
1-Year Change
-56.83%
Shares Outstanding
143,276,594
Next Earnings Date
-
What is your sentiment on Cynata Therapeutics Ltd?
or
Market is currently closed. Voting is open during market hours.

Cynata Therapeutics Ltd News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsSellSellSellSellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Cynata Therapeutics Ltd Company Profile

Cynata Therapeutics Ltd Company Profile

Employees
2
Market
Australia

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Cremorne, Australia.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.